J&J’s $6.5B Momenta Buy Pays Off With Phase II Sjögren’s Disease Win

Johnson & Johnson on Saturday posted promising data from the Phase II DAHLIAS study of its investigational FcRn blocker nipocalimab, demonstrating significant symptomatic improvement in patients with the chronic autoimmune Sjögren’s disease.